HC Wainwright disclosed Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), bumping its price target to $5.00 earlier today
- Updated: November 29, 2016
Indicating a possible upside of 0.70%, HC Wainwright raised the target price of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) to $5.00
Previously on 11/28/2016, Rodman & Renshaw released a statement about Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) increased the target price from $0.00 to $5.00. At the time, this indicated a possible upside of 0.92%.
Just yesterday Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) traded -5.78% lower at $2.94. Imprimis Pharmaceuticals Inc’s 50-day moving average is $2.78 and its 200-day moving average is $3.61. The last stock price is down -23.19% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 122,227 shares of IMMY traded hands, up from an average trading volume of 56,947
Recent Performance Chart
Imprimis Pharmaceuticals Inc has 52 week low of $2.22 and a 52 week high of $7.81 and has a market cap of $0.
General Information About Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)
Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.